Across TCGA pan-cancer cohorts, RNY4P29 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated RNY4P29 data layer.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNY4P29 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNY4P29 expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.
LIHC, DLBC, and PAAD are the cancer types where RNY4P29 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.